We Think That There Are Issues Underlying Pacira BioSciences' (NASDAQ:PCRX) Earnings

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) stock was strong after they recently reported robust earnings. However, we think that shareholders may be missing some concerning details in the numbers. N

Simply Wall StMay 14 18:26

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes Due 2029

PDF Version TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior no

Pacira BioSciencesMay 10 12:00

Pacira Biosciences Announces Proposed Offering of $250M Aggregate Principal Amount of Convertible Senior Notes

Seeking AlphaMay 9 04:36

Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow JonesMay 9 03:35

HC Wainwright & Co. : Pacira BioSciences (PCRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $57.00.

HC Wainwright & Co. : Pacira BioSciences (PCRX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $57.00.

Zhitong FinanceMay 9 03:31

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target

HC Wainwright & Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $57 price target.

BenzingaMay 9 03:25